Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Purchasing Commitments Must Underpin US Expansion

AAM Industry Association Sets Out Blueprint For US Supply Chain

Executive Summary

In an attempt to strengthen the US generic drug supply chain and reduce dependence on certain countries for supply, the AAM has proposed a policy framework “blueprint” that requires government purchasing commitments in exchange for industry manufacturing expansion.

You may also be interested in...

Phlow CEO Reveals Possible Partnerships With ‘Global Generics Manufacturing Companies’

In the second part of an exclusive interview with Generics Bulletin, Phlow CEO Eric Edwards has revealed that the company is at the precipice of entering into agreements to co-develop essential medicines in the US. Edwards has also recognized the Biden administration’s efforts to secure domestic supply, offering suggestions on how to fix “America’s broken supply chain.”

AAM CEO ‘Not Fully Aligned With Biden Administration On Pay-For-Delay Ban’

In an exclusive interview with Generics Bulletin, US Association for Accessible Medicines CEO Dan Leonard has expressed concerns over the blanket change to patent settlements introduced by Joe Biden’s recent executive order. Furthermore, Leonard expects to see a “robust decade” for generic drugs, biosimilars and complex generics as many major brands are set to lose their exclusivity.

Lupin CEO Says Additional incentives Needed To Make US Manufacturing Viable

Lupin CEO Vinita Gupta has insisted that additional incentives are necessary to make local manufacturing in the US viable. The recently-launched podcast by the US Association for Accessible Medicines, with CEO Dan Leonard as the host, welcomed Gupta who shared details of Lupin’s strategy and how the company plans to keep a firm foot in affordable medicines. 

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts